Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Ewa Lech-Maranda, Ewa Robak and Tadeusz Robak
Affiliation: Department of Hematology, Medical University of Lodz, Copernicus Hospital, Ciolkowskiego 2 st, 93-510 Lodz, Poland.
Keywords: Bexarotene, cutaneous T-cell lymphoma, denileukin diftitox, histone deacetylase inhibitors, mycosis fungoides, Sezary syndrome, KIR3DL2, Retinoids, retinol, arotinoids, isotretinoin, RAR, RXR, promising results, therapy (PUVA), PPAR, NIDDM, hypergly-cemia, hypertriglyceridemia, hyper-insulinemia, HepG2 cells, HOX, skin desquamation, hyperbiliru-binemia, transaminase elevation, leukopenia, diarrhea, hypothyroidism, extracorporeal photopheresis, Escherichia coli, ADP-ribosylation, vascular leak syndrome, GvHD, PTCL, hairy cell leukemia, adult T-cell lymphoma, Pegasys, insomnia, anorexia, IRMs, CTCL, trichostatin A, vorinostat, Chromobacterium violaceum, ZVAD-FMK, thioredoxin, FK228, redFK228, romidepsin, PBMCs, peripheral T-cell lymphoma, HMBA, SAHA, Zolinza, pulmonary embolism, thrombocytopenia, Alemtuzumab, Campath, Listeria meningitidis, Legionella pneumonia, Cytomegalovirus, Pneumocystis carini, Zanolimumab, rheumatoid arthritis, psoriasis, forodesine, Pralatrexate, methotrexate
For the last few years new therapeutic options for primary cutaneous T-cell lymphoma (CTCL) have been recently introduced into clinical trials, particularly for patients with advanced stage and refractory disease. Systemic treatment uses biological response modifiers, such as fusion molecules, rexinoids, interferons as well as monoclonal antiobodies, and new antiproliferative drugs, such as histone deacetylase inhibitors, proteasome inhibitors or forodesine. This review focuses on recent advances in the development of systemic agents for CTCL including both novel patented compounds and novel therapeutic protocol of intervention.
Rights & PermissionsPrintExport